Scythian Biosciences

15 articles about Scythian Biosciences

• SOL Global to Spin Off Cannabinoid Drug Therapy Research and Development Subsidiary

  4/5/2019

  Former CEO to Take Lead in Spin Off Company

• Scythian Biosciences Appoints Brady Cobb as CEOCompany Also Names Andy DeFrancesco Chief Investment Officer

  10/3/2018

  Scythian Biosciences Corp. announced today Brady Cobb, a leading voice in the medical cannabis industry, has been appointed Chief Executive Officer.

• A Tipping Point in Global Marijuana Markets

  7/27/2018

  Scythian Biosciences Corp. is a tiny company with a big secret.

• Scythian Announces Strategic Sale of Latin American and Caribbean Assets in $193,000,000 Deal to Aphria

  7/17/2018

  Sale of Assets Transforms Scythian Into a Highly Liquid and Well Capitalized Company with Over $200 million in Cash and Marketable Securities on Hand

• Scythian Biosciences Announces Appointment of Professor Michael Barnes as CMO

  2/15/2018

  Professor Barnes MD FRCP is considered to be a leading world authority in neurological rehabilitation and has emerged as an influential voice in medical cannabis policy in Europe.

• Scythian Biosciences Corp. Announces Approval for Listing on the Nasdaq Capital Markets under Symbol “SCYB” and Ringing of the Nasdaq Closing Bell

  2/14/2018

  Scythian will ring the closing bell at the Nasdaq MarketSite in Times Square, New York City on February 22, 2018.

• Scythian Biosciences Announces Closing of $28.7M Financing With Aphria as Lead Investor

  2/13/2018

  A total of 772,943 units of the Company were sold at a price of $18.60 per Unit for gross proceeds of C$14,376,740.

• Scythian Biosciences Announces CEOs of Both Aphria and Liberty Health Sciences are Joining its Board

  1/15/2018

  Along with their great expertise and backgrounds, Mr. Neufeld and Mr. Scorsis will also bring to Scythian new relationships and allow Scythian to expand its business globally.

• Scythian Biosciences Corp. Announces Upgrade to the OTCQB Marketplace

  1/10/2018

  The company's mission is to be the first accepted drug regimen for concussive treatment.

• Scythian Biosciences Corp. Announces Proposed Up To 8 for 1 Stock Split

  1/4/2018

  Scythian has approximately 5.43 million common shares currently outstanding, and after giving effect to the maximum proposed eight (8) for one (1) stock split, Scythian will have approximately 43.4 million common shares outstanding.

• Scythian Announces No Material Change

  12/29/2017

  Scythian is also unaware of any material undisclosed change related to the Company that would explain the recent movements in the price of its common shares.

• Scythian Biosciences Corp. Announces Appointment of Ottis Anderson to Pro Athlete Advisory Committee

  12/12/2017

  The Company has also issued an additional 8,750 stock options with an exercise price of $8.65 per share for a period of five years, as well as 56,250 deferred share units to officers of the Company.

• Scythian Biosciences Completes Sale of Go Green

  11/30/2017

  In addition to the cash compensation received, 27,000 common shares of Scythian are being returned to treasury for cancellation.

• Scythian Biosciences Forms Professional Athlete Advisory Committee

  9/28/2017

• Scythian Biosciences Appoints Chief Scientific Officer

  9/5/2017